Cardiovascular risk in children and adolescents with end stage renal disease

Abstract

OBJECTIVES:

To evaluate cardiovascular involvement in children and adolescents with End Stage Renal Disease (ESRD) and to characterize the main risk factors associated with this outcome.

METHODS:

Cross-sectional study of 69 children and adolescents at renal transplantation and 33 healthy individuals matched by age and gender. The study outcomes were left ventricular mass z-score (LVMZ) and carotid artery intima-media thickness (CIMT). The potential risk factors considered were age, gender, CKD etiology, use of oral vitamin D and calcium-based phosphate binders, systolic and diastolic blood pressure, body mass index z-score, time since diagnosis, dialysis duration, serum levels of ionic calcium, phosphorus, parathyroid hormone, fibroblast growth factor (FGF 23), uric acid, homocysteine, cholesterol, triglycerides, C-reactive protein (CRP), vitamin D and hemoglobin.

RESULTS:

In the multivariate analysis, the factors associated with LVMZ were dialysis duration, age, systolic blood pressure, serum hemoglobin and HDL cholesterol levels. Regarding CIMT, in the multivariate analysis, systolic blood pressure was the only factor associated with the outcome.

CONCLUSION:

Children exhibited important cardiovascular involvement at the time of the renal transplantation. Both of the studied outcomes were independently associated with systolic blood pressure. For this reason, controlling blood pressure seems to be the main therapy to minimize cardiovascular involvement in children with ESRD.

Chronic Kidney Disease; Cardiovascular Disease; Children; Intima-Media Thickness; Ecocardiography

INTRODUCTION

Chronic kidney disease (CKD) is a public health concern for adult and pediatric patients (¹). In 2010, 2,618 million people in the world underwent renal replacement therapy (RRT) (²), and the prevalence of children undergoing RRT in Brazil was 20 cases per million individuals in this age group in 2012 (³).

Cardiovascular disease (CVD) is a leading cause of death in pediatric CKD patients (⁴-⁷). In children undergoing dialysis, the mortality associated with cardiac disease is one thousand times higher than in normal children (⁷). CVD was the main cause of death in patients undergoing dialysis, affecting 33% of cases in a cohort of US children followed from 1995 to 2010 (⁸).

In adults with CKD, CVD results from an interaction of risk factors that are grouped into a) traditional factors, such as hypertension, diabetes, hypercholesterolemia, smoking, sedentary lifestyle, white ethnicity, aging, glucose intolerance, psychosocial stress, family history of heart disease, malnutrition, obesity and male gender; and b) non-traditional factors associated with CKD (⁹,¹⁰). The CKD associated factors are either hemodynamic (volume overload, arteriovenous fistula and anemia) or metabolic, such as oxidative stress; inflammation; hyperhomocysteinemia; proteinuria; increased renin-angiotensin-aldosterone activity; abnormal calcium, phosphorus and vitamin D metabolism; increased serum FGF-23 levels; dyslipidemia; hypoalbuminemia; increased pro-thrombotic factor levels; endothelial dysfunction and infection (Chlamydia pneumoniae) (¹¹). When compared to adult patients, children with CKD are less exposed to traditional risk factors (¹²), which allows for privileged observation of the role of non-traditional factors.

Considering that infarction and stroke are late events not usually experienced in the pediatric age range, we evaluated cardiovascular changes in children and adolescents with CKD at the time of renal transplantation (RT), considering echocardiography and carotid ultrasound as surrogate endpoints, i.e., substitutes for late clinical events. These changes have already been described in children and adolescents in economically developed countries, but reports are scarce in countries in the southern hemisphere.

The present study aimed to evaluate cardiovascular involvement in children and adolescents with ESRD at the time of (RT) using echocardiography and carotid ultrasound. Additionally, we aimed to characterize the main risk factors associated with these outcomes.

METHODS

We performed a cross-sectional study of 69 patients aged 18 years or less who underwent (RT) at Hospital do Rim-UNIFESP. A control group of healthy children paired by sex and age who were treated in the adolescents outpatient service from the same institution was also included. The data were collected from March 2012 to December 2014.

The study was approved by the Ethics and Research Committee of the Federal University of São Paulo (Protocol 2031/11). All patients enrolled in the study signed a consent form.

The exclusion criteria were: congenital or structural cardiac abnormalities and primary myocardial disease; children with active infectious disease, characterized by fever and bacteremia, or under antimicrobial treatment; diabetes, active inflammatory diseases (e.g., vasculitis and systemic lupus erythematosus), or genetic or endocrine diseases with disorders in calcium or phosphorus metabolism; smoking (in adolescents); and the presence of a venous catheter near the carotids.

Left ventricular mass z-score (LVMZ) measured by echocardiography and carotid artery intima-media thickness (CIMT) measured by carotid ultrasound in both groups were expressed as a continuous quantitative variable.

The following risk factors were considered: age at transplantation, gender, body mass index z-score, time (months) since CKD diagnosis, duration (months) of dialysis before the renal transplantation, etiology of the CKD (undetermined, urinary tract malformation, glomerulopathies, other diagnoses), systolic blood pressure (SBP), diastolic blood pressure, serum hemoglobin levels, serum albumin levels, serum total cholesterol levels, serum HDL cholesterol levels, serum triglycerides levels, C-reactive protein (CRP), uric acid, homocysteine, serum ionic calcium levels, serum phosphorus levels, serum calcium x phosphorus product levels (CaxP product), serum parathyroid hormone (PTH) levels, serum fibroblast growth factor (FGF23) levels, serum vitamin D levels, vitamin D use and use of calcium-based phosphate binders (categorically evaluated as yes or no, with no confirmation of the time of use or adherence).

To prevent the requirement of invasive and painful procedures in healthy individuals, blood sampling was not performed in the control group.

Evaluation of the Left Ventricular Mass Z-Score Outcome

After a median follow-up of 24 days (IQR=16 to 30) following RT transthoracic color Doppler echocardiography was performed by 1 of 2 expert physicians using a standard VIVID 7 dimension device (General Electric® Healthcare) with a 5-mHz transducer. To calculate the left ventricular mass Z-scores (LVMZ), Parameter Z software was used according to the American Society of Echo's Guidelines and Standards for Performance of a Pediatric Echocardiogram (¹³).

We used American Society of Echocardiography guidelines (iASE version 3.0.4) to evaluate the left ventricular mass index (LVMI), including relative wall thickness and left ventricular geometry. Diastolic dysfunction was evaluated with tissue Doppler and expressed as a binary variable (present or absent diastolic dysfunction) (¹⁴).

Evaluation of Carotid Artery Intima-Media Thickness

All ultrasound exams were performed by the same examiner using a 3-12-MHz multi-frequency linear transducer device (LOGIQ 7, General Electric Health Care®). The patients were maintained in slight neck hyperextension with the chin slightly rotated laterally in the opposite direction to the transducer after at least ten minutes of rest (¹⁵).

The CIMT measure was defined as the distance between the edges of the lumen-intimal interface and the medial-adventitial interface of the distal wall, measured bilaterally in the common carotid artery 1 cm below the bifurcation (¹⁶). Two measures were manually performed with the caliper method on each artery scan and the mean of the results was calculated.

For the control group, the echocardiogram and carotid ultrasound were obtained using the same methodology as for the study group.

Statistical Analysis

The data were expressed as the mean and standard deviation or median and interquartile range (IQR) according to the distribution of the variables. To compare the two groups, we used Student’s t-test for quantitative variables and the chi-squared test or Fisher’s exact test for proportions.

To evaluate a possible association between risk factors and outcomes (left ventricular mass z-score and carotid artery intima-medial thickness), a simple linear regression model was used for each outcome. Then, variables with p<0.10 in the simple linear regression were selected for inclusion in a multivariate linear regression model. In the multivariable models we included up to 5 potential risk variables to respect the proportion of introducing one risk variable for each 10 to 15 individuals in the sample. The covariables that did not exhibit a significant association with the studied outcome were removed one by one (i.e., the backward selection method). Lastly, the interaction terms between the variables that remained in the final models were investigated.

For all of the tests, a limit of p<0.05 was adopted to reject the null hypothesis, and all calculations were performed using Stata software 14.2® (College Station, TX77845, USA).

The study was approved by the Ethics and Research Committee of the Federal University of São Paulo (Protocol 2031/11). All patients enrolled in the study signed a consent form.

RESULTS

During the data collection, there were 79 pediatric transplants, with all the recipients being candidates for participation in the study. Two refused to participate and eight were excluded, four for infections and four because they did not attend the hospital for the examinations.

The demographic, anthropometric and clinical data of the study sample are presented in Table 1. There were no significant differences regarding age or sex between the groups, whereas the weight, height and BMI z-score were significantly lower in ESRD children.

Table 1
Demographic, anthropometric and clinical data of the sample according to the study group.

Variable	Cases (n=69)	Controls (n=33)	p
Mean Age in Years (SD)	13.1 (4.6)	13.0 (3.7)	0.967
Gender (Male/Female)	39/30	17/16	0.635
Mean Weight in kg (SD)	38.4 (17.1)	47.6 (14.3)	0.009
Mean Height in cm (SD)	141.7 (25.6)	152.1 (18.5)	0.042
H/A Z-Score (SD)	-1.6 (1.5)	-0.1 (0.9)	<0.001
BMI Z-Score (SD)	-0.6 (1.5)	0.3 (0.8)	0.001
Pubescent/Pre-pubescent	40/17	25/8	0.568
Months Since Diagnosis (IQR)	35 (13 to 72)	NA	NA
Months Undergoing Dialysis (IQR)	14 (8 to 23)	NA	NA
Urinary Tract Malformation (n/total)	26/69	NA	NA
Systolic Blood Pressure (mmHg)	122 (21)	99 (11)	<0.001
Diastolic Blood Pressure (mmHg)	76 (15)	59 (9)	<0.001

• SD-Standard deviation of the mean, H/A-Height/Age, BMI-Body mass index, NA-Not applicable, IQR-Interquartile range of the median.

Regarding the etiology of CKD, there were 26 cases of urinary tract malformations (38%), 16 cases of glomerulopathies (23%), 23 cases of undetermined diseases (33%) and four children with other diagnoses (6%).

The median time span since the CKD diagnosis to RT was 35 months (IQR=13–72), and the median duration of RRT was 14 months (IQR=8–23). In 7/69 cases (10%), a preemptive RT was performed. Among the remaining 62 patients, the dialysis methods were exclusive hemodialysis (HD) in 35 patients (51%), exclusive peritoneal dialysis (PD) in 14 cases (20%), and both HD and DP in 13 (19%) cases. Regarding the type of RT, 65 children (94%) received a deceased-donor kidney.

The blood pressure values were higher among ESRD children when compared to controls. Among cases, 44 patients (64%) used antihypertensive drugs and 16 had stage 1 hypertension (¹⁷), 9 had stage 2, 5 were pre-hypertensive, and 14 had normal blood pressure. In the group of patients not using antihypertensive drugs, 4 had high blood pressure levels: two with stage 1 hypertension, one with stage 2, and one with pre-hypertension. None of the individuals from the control group required hypertension medication, and all of them had normal blood pressure.

Echocardiographic Parameters

The left ventricular mass z-score (LVMZ) was 0.48 (SD=1.75) in CKD patients and -0.94 (SD=1.00) in patients from the control group, displaying a significant difference between groups (Figure 1). The LVMZ was increased (>2) in 14 patients among cases (20%) and in no individuals from the control group.

Figure 1
Left ventricular Z-score according to study group.

Among patients with CKD, 42 children (60.9%) exhibited normal left ventricular geometry, whereas concentric hypertrophy was observed in 14 patients (20.3%), eccentric hypertrophy in 11 patients (15.9%) and concentric remodeling in two other (2.9%). Conversely, all individuals from control group had normal left ventricular geometry (p<0.001).

The left ventricular systolic function was preserved in all of the patients, except for one case that exhibited moderate dysfunction. All of the controls had normal function. The analysis of the diastolic function was not possible in one case due to tachycardia. Nine patients with CKD (13%) exhibited altered diastolic dysfunction (13%), whereas controls were normal (p<0.001).

The results of the univariate and multivariate linear regression are compiled in Table 2.

Table 2
Univariate and multivariate linear regression analysis of risk factors associated with left ventricular mass Z-score.

Variable	Coefficient	CI	p	Coefficient	CI	p
Age	0.084	0.013 to 0.155	0.020	0.083	0.009 to 0.157	0.028
Gender	-0.334	-1.008 to 0.339	0.328
Body Mass Index (BMI)	-0.055	-0.362 to 0.251	0.720
Time Since Diagnosis	0.000	-0.008 to 0.008	0.991
Dialysis Duration	0.017	-0.002 to 0.037	0.082	0.017	0.002 to 0.031	0.020
Urinary Tract malformation	-0.755	-1.562 to 0.050	0.066	NS
Systolic Blood Pressure	0.038	0.024 to 0.051	0.000	0.024	0.005 to 0.043	0.011
Diastolic Blood Pressure	0.045	0.025 to 0.065	0.000	NS
Serum Hemoglobin (g/dL)	-0.214	-0.416 to -0.013	0.037	-0.204	-0.379 to -0.028	0.023
Serum Albumin (g/dL)	0.310	-0.255 to 0.876	0.277
Serum Cholesterol (mg/dL)	-0.002	-0.011 to 0.006	0.555
Serum HDL (mg/dL)	-0.048	-0.086 to -0.011	0.012	-0.040	-0.075 to -0.005	0.026
Serum TG (mg/dL))	0.002	-0.002 to 0.006	0.377
Serum CRP (mg/dL)	0.157	-0.234 to 0.549	0.425
Serum Uric Acid (mg/dL)	-0.064	-0.289 to 0.160	0.570
Serum Homoc (μmol/dL)	0.011	-0.033 to 0.568	0.613
Serum Ionic Calcium(mg/dL)	-4.065	-8.990 to 0.859	0.104
Serum Phosphorus (mg/dL)	0.166	-0.101 to 0.434	0.219
CaxP Product (mg/dL)	0.010	-0.019 to 0.040	0.475
Serum PTH (pg/mL)	0.000	-0.000 to 0.001	0.145
Serum FGF23 (pg/mL)	0.000	0.000 to 0.000	0.038	NS
Serum Vitamin D (ng/dL)	0.011	-0.021 to 0.043	0.500
Vitamin D Use	0.806	-1.674 to 0.062	0.068	NS
Use of Phosphate Binders	-0.130	-1.106 to 0.845	0.790

In this model, among all the nine pre-selected covariables, we opted to exclude four in order to comply with the proportion of including one counfounder for each ten to fifteen individuals in the sample. Hence, we excluded DBP because it was strongly correlated with SBP and also etiology of the CKD, serum FGF23 and vitamin D use because these were the variables with less previously published evidence to explain changes in left ventricular mass. All the selected five factors showed a significant association with LVMZ in this model: dialysis duration, age at transplantation, SBP, serum hemoglobin levels and serum HDL levels. The details of these associations are as follows: for each 1-month increase in dialysis duration, a 0.017 SDS increase in LVMZ is observed; for each additional year of age at RT, a 0.08 SDS increase in LVMZ is expected; each 1 mmHg increase in SBP is associated with a 0.024 SDS increase in LVMZ; for each 1 g/dL increase in serum hemoglobin, a 0.20 SDS decrease in LVMZ is expected; and for each 1 mg/dL increase in HDL, a decrease of 0.04 SDS in LVMZ is predicted. The analysis of the interaction between these variables did not show significant effects, suggesting that these associations with LVMZ are independent.

Analysis of the Carotid Artery Intima-Medial Thickness

When comparing the carotid artery intima-medial thickness (CIMT), we found a significant difference between the groups, with a greater thickness in patients with ESRD (0.52±0.10 mm versus 0.46±0.07 mm, p=0.028). This result demonstrates arterial involvement in children with ESRD, as illustrated in Figure 2. The linear regression analyses for this outcome are compiled in Table 3.

Age, SBP, diastolic blood pressure (DBP) and vitamin D use exhibited an association with CIMT and were included in the multivariate linear regression model, after which there was only an association with SBP. According to this analysis, each 10-mmHg increase in SBP was associated with an increase of 0.015 mm in CIMT.

Figure 2
Carotid artery intima-medial thickness according to study group.

Table 3
Univariate and multivariate analysis of risk factors associated with left carotid artery intima-medial thickness.

Variable	Coefficient	CI	p	Coefficient	CI	p
Age	0.005	0.001 to 0.010	0.013	0.003	-0.001 to 0.008	0.122
Gender	-0.013	-0.050 to 0.023	0.478
Body Mass Index (BMI)	-0.008	-0.021 to 0.003	0.168
Time Since Diagnosis	-0.000	-0.000 to 0.000	0.559
Dialysis Duration	-0.000	-0.001 to 0.000	0.733
Urinary Tract Malformation	-0.021	-0.066 to 0.024	0.364
Systolic Blood Pressure	0.001	0.000 to 0.002	0.001	0.001	0.000 to 0.002	0.009
Diastolic Blood Pressure	0.001	0.000 to 0.003	0.001	0.000	-0.001 to 0.003	0.532
Serum Hemoglobin (g/dL)	-0.005	-0.016 to 0.004	0.251
Serum Albumin (g/dL)	0.022	-0.006 to 0.050	0.122
Serum Cholesterol (mg/dL)	-0.000	-0.000 to 0.000	0.176
Serum HDL (mg/dL)	0.001	-0.000 to 0.003	0.181
Serum TG (mg/dL)	-0.000	-0.000 to 0.000	0.181
Serum CRP (mg/dL)	-0.004	-0.020 to 0.010	0.535
Serum Uric Acid (mg/dL)	0.001	-0.013 to 0.015	0.881
Serum Homoc (μmol/dL)	0.002	-0.001 to 0.006	0.251
Serum Ionic Calcium (mg/dL)	0.078	-0.134 to 0.291	0.467
Serum Phosphorus(mg/dL)	-0.006	-0.023 to 0.010	0.450
CaxP Product (mg/dL)	-0.000	-0.002 to 0.001	0.649
Serum PTH (pg/mL)	-0.000	-0.000 to 0.000	-0.500
Serum FGF23(pg/mL)	-0.000	-0.000 to 0.000	0.684
Serum Vitamin D (ng/mL)	-0.000	-0.001 to 0.001	0.924
Vitamin D Use	-0.058	-0.103 to -0.013	0.011	-0.031	-0.081 to 0.019	0.221
Use of Phosphate Binders	0.024	-0.025 to 0.074	0.333

DISCUSSION

The main finding of the present study was that ESRD children and adolescents exhibited cardiovascular involvement at the time of RT presenting increased LVM and CIMT when compared to controls. Such outcomes are substitutes for late clinical events at the pediatric age range. However, these outcomes are relevant because they are recognized risk factors for predictable clinical outcomes, especially in adults (¹⁸,¹⁹).

Cardiac abnormalities are frequent in adults and children with CKD and contribute to morbidity (⁷,⁹,²⁰). In adults, a prospective study evaluating 161 patients undergoing HD showed that each 1 g/m^2.7 increase in LVMI was associated with a 62% increase in the risk of adverse cardiovascular events. This association suggests that changes in LVM have independent prognostic value for cardiovascular events, reinforcing echocardiography as a tool for monitoring cardiovascular risk in patients undergoing dialysis (²¹).

Left ventricular hypertrophy (LVH) is common in pediatric and adult patients undergoing dialysis (⁹). This change may occur early and has a prevalence ranging from 30% in mild to moderate CKD (²²) to 73% in children undergoing dialysis (²³-²⁶). There are different methods for indexing LVM, a topic that is widely discussed in the literature (²²,²⁵,²⁷). In this research, considering that LVM is influenced by the age and size of pediatric patient, we opted to use the LVM z score to express the magnitude of the deviation from the mean (²⁸). In study involving children in different stages of CKD, the use of the z-score allowed for the identification a higher LVH proportion in the dialysis group when compared to other criteria, such as LVM indexed to body surface area (²⁷).

The first variable that exhibited an independent association with LVMZ was age at RT, which is biologically plausible. However, because we use the z score to express the LVM, the effect of age on any body size measurement was attenuated. Therefore, this association is likely related to CKD and not simply due to LVM increase with age. In addition to age, we observed the effect of dialysis duration on LVMZ and it is possible that the association between LVM and age is somehow related to dialysis duration. In contrast to our findings, the association between LVM and dialysis duration was not found in another study involving 64 patients undergoing dialysis (²⁹). However this study was retrospective, and we believe that our finding highlights the importance of limiting dialysis duration and encouraging preemptive RT to decrease the frequency of LVH.

Another finding was the association between serum hemoglobin and LVM, which is consistent with data from the literature that reports an association between anemia and LVMI (²²,³⁰). In a cross-sectional study evaluating 156 children undergoing dialysis with similar mean age to that of our study, an independent association between low serum hemoglobin and LVMI was reported (²²). In agreement to these findings, a more recent study on 46 patients undergoing dialysis also showed anemia and hypertension as predictive factors of LVMI in patients 5 to 21 years of age (³⁰).

Amongst the potential risk factors tested in the present study, only SBP exhibited an association with both of the studied outcomes. This finding agrees with most studies in the literature (²²,²⁴,³¹,³²) and has implications for daily clinical practice, reinforcing the need for strict control of this parameter in CKD patients. Specifically in children undergoing dialysis, an association between hypertension and LVH was reported in another study on Brazilian children (³³). Moreover, if we consider that hypertension is common in both the short- (³⁴) and long term (³⁵) following RT in children, adequate diagnosis and treatment of this complication has increased importance to reduce the risk for cardiovascular complications in all stages of CKD. It is worth noting that data from another cross-sectional study showed an association between SBP and LVMI even in non-hypertensive CKD patients, suggesting that the target in current recommendations for controlling the SBP must be reconsidered (²⁴).

Low serum HDL is associated with increased coronary disease in adults with CKD, and lower baseline concentrations when compared to the general population have been reported. These lipid abnormalities may produce a 1.2-1.4-fold higher risk for coronary disease (³⁶). Our findings confirm the possibility that decreasing serum HDL cholesterol in children increases LVM, which may have implications for the clinical treatment of these patients.

Previous studies have reported normal CIMT values in children from the northern hemisphere (¹⁶,³⁷) as well as in Brazil (³⁸). However, such studies are scarce and not internationally validated. For this reason, we chose not to calculate the CIMT z-score and our analyses were performed with the absolute value of this measure. In a study that evaluated patients aged between 10 and 20 years of age without cardiovascular disease, associations between CIMT and age and also between body size and blood pressure were observed in healthy adolescents (¹⁶). Similarly, in a European multicenter study, a significant relationship was found between the SBP z-score and BMI as independent positive predictors associated with CIMT (³⁷).

In a study evaluating 101 children aged between 2 and 18 years of age and healthy controls, dyslipidemia and hypertension were associated with an increase of in the CIMT, (³⁹). We also found a significant association between SBP with CIMT, and there was no association with calcium, phosphorus, gender or CKD etiology, which is similar to the findings of Litwin et al. (¹²).

The results of the present study must be interpreted considering its limitations. The first is the cross-sectional design of the study, which prevents the establishment of causal relationships between risk factors and the studied outcomes. The development of cardiovascular complications is a process that occurs over time, and cross-sectional studies, only one time point in this progression can be evaluated. Another study feature that prevented us from formulating more in-depth analyses was the lack of data on both dialysis quality and the duration of the medications that the patients were receiving. The fact that patients of the study had been referred for from different regions of the country precluded access to their medical records in the dialysis clinics of origin, rendering it impossible to obtain data on prescription duration, changes in dosages and adherence. This factor limited our analysis of the role of dialysis quality and the use of calcium-based phosphate binders, vitamin D analogs and antihypertensive medications.

Nevertheless we believe that our findings indicate that there is significant cardiovascular involvement in at least 1/5 of pediatric ESRD patients at the time of RT. We concluded that children with CKD show cardiac involvement and that the control of modifiable risk factors as hypertension and anemia must be considered therapeutic aims. The independent association between SBP and both markers suggests an opportunity for interventions that aim to prevent cardiovascular complications.

ACKNOWLEDGMENTS

This study was supported by São Paulo Research Foundation – FAPESP. Process 2011/24030-0.

REFERENCES

• ¹
  Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27(3):363-73, https://doi.org/10.1007/s00467-011-1939-1
  » https://doi.org/10.1007/s00467-011-1939-1
• ²
  Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975-82, https://doi.org/10.1016/S0140-6736(14)61601-9
  » https://doi.org/10.1016/S0140-6736(14)61601-9
• ³
  Konstantyner T, Sesso R, de Camargo MF, de Santis Feltran L, Koch-Nogueira PC. Pediatric Chronic Dialysis in Brazil: Epidemiology and Regional Inequalities. PLoS One. 2015;10(8):e0135649, https://doi.org/10.1371/journal.pone.0135649
  » https://doi.org/10.1371/journal.pone.0135649
• ⁴
  Litwin M, Grenda R, Prokurat S, Abuauba M, Latoszyãska J, Jobs K, et al. Patient survival and causes of death on hemodialysis and peritoneal dialysis--single-center study. Pediatr Nephrol. 2001;16(12):996-1001, https://doi.org/10.1007/s004670100012
  » https://doi.org/10.1007/s004670100012
• ⁵
  Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, et al. Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int. 2002;61(2):621-9, https://doi.org/10.1046/j.1523-1755.2002.00156.x
  » https://doi.org/10.1046/j.1523-1755.2002.00156.x
• ⁶
  Rinat C, Becker-Cohen R, Nir A, Feinstein S, Shemesh D, Algur N, et al. A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrol Dial Transplant. 2010;25(3):785-93, https://doi.org/10.1093/ndt/gfp570
  » https://doi.org/10.1093/ndt/gfp570
• ⁷
  Parekh RS, Carroll CE, Wolfe RA, Port FK. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 2002;141(2):191-7, https://doi.org/10.1067/mpd.2002.125910
  » https://doi.org/10.1067/mpd.2002.125910
• ⁸
  Chavers BM, Molony JT, Solid CA, Rheault MN, Collins AJ. One-year mortality rates in US children with end-stage renal disease. Am J Nephrol. 2015;41(2):121-8, https://doi.org/10.1159/000380828
  » https://doi.org/10.1159/000380828
• ⁹
  Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol. 2008;23(1):27-39, https://doi.org/10.1007/s00467-006-0359-0
  » https://doi.org/10.1007/s00467-006-0359-0
• ¹⁰
  Guérin AP, Pannier B, Marchais SJ, London GM. Arterial structure and function in end-stage renal disease. Curr Hypertens Rep. 2008;10(2):107-11, https://doi.org/10.1007/s11906-008-0021-2
  » https://doi.org/10.1007/s11906-008-0021-2
• ¹¹
  Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M. Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol. 2012;27(11):2129-36, https://doi.org/10.1007/s00467-012-2224-7
  » https://doi.org/10.1007/s00467-012-2224-7
• ¹²
  Litwin M, Wühl E, Jourdan C, Niemirska A, Schenk JP, Jobs K, et al. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant. 2008;23(8):2552-7, https://doi.org/10.1093/ndt/gfn083
  » https://doi.org/10.1093/ndt/gfn083
• ¹³
  Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70, https://doi.org/10.1093/ehjci/jev014
  » https://doi.org/10.1093/ehjci/jev014
• ¹⁴
  Lindblad YT, Axelsson J, Balzano R, Vavilis G, Chromek M, Celsi G, et al. Left ventricular diastolic dysfunction by tissue Doppler echocardiography in pediatric chronic kidney disease. Pediatr Nephrol. 2013;28(10):2003-13, https://doi.org/10.1007/s00467-013-2504-x
  » https://doi.org/10.1007/s00467-013-2504-x
• ¹⁵
  Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(1):75-80, https://doi.org/10.1159/000097034
  » https://doi.org/10.1159/000097034
• ¹⁶
  Jourdan C, Wühl E, Litwin M, Fahr K, Trelewicz J, Jobs K, et al. Normative values for intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens. 2005;23(9):1707-15, https://doi.org/10.1097/01.hjh.0000178834.26353.d5
  » https://doi.org/10.1097/01.hjh.0000178834.26353.d5
• ¹⁷
  Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58(6):1072-83, https://doi.org/10.1161/01.CIR.58.6.1072
  » https://doi.org/10.1161/01.CIR.58.6.1072
• ¹⁸
  O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14-22, https://doi.org/10.1056/NEJM199901073400103
  » https://doi.org/10.1056/NEJM199901073400103
• ¹⁹
  Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36(2):286-90, https://doi.org/10.1038/ki.1989.192
  » https://doi.org/10.1038/ki.1989.192
• ²⁰
  Chavers BM, Li S, Collins AJ, Herzog CA. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 2002;62(2):648-53, https://doi.org/10.1046/j.1523-1755.2002.00472.x
  » https://doi.org/10.1046/j.1523-1755.2002.00472.x
• ²¹
  Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65(4):1492-8, https://doi.org/10.1111/j.1523-1755.2004.00530.x
  » https://doi.org/10.1111/j.1523-1755.2004.00530.x
• ²²
  Matteucci MC, Wühl E, Picca S, Mastrostefano A, Rinelli G, Romano C, et al. Left ventricular geometry in children with mild to moderate chronic renal insufficiency. J Am Soc Nephrol. 2006;17(1):218-26, https://doi.org/10.1681/ASN.2005030276
  » https://doi.org/10.1681/ASN.2005030276
• ²³
  Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol. 2010;21(1):137-44, https://doi.org/10.1681/ASN.2009060609
  » https://doi.org/10.1681/ASN.2009060609
• ²⁴
  Sinha MD, Tibby SM, Rasmussen P, Rawlins D, Turner C, Dalton RN, et al. Blood pressure control and left ventricular mass in children with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(3):543-51, https://doi.org/10.2215/CJN.04690510
  » https://doi.org/10.2215/CJN.04690510
• ²⁵
  Simpson JM, Savis A, Rawlins D, Qureshi S, Sinha MD. Incidence of left ventricular hypertrophy in children with kidney disease: impact of method of indexation of left ventricular mass. Eur J Echocardiogr. 2010;11(3):271-7, https://doi.org/10.1093/ejechocard/jep211
  » https://doi.org/10.1093/ejechocard/jep211
• ²⁶
  Johnstone LM, Jones CL, Grigg LE, Wilkinson JL, Walker RG, Powell HR. Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int. 1996;50(3):998-1006, https://doi.org/10.1038/ki.1996.401
  » https://doi.org/10.1038/ki.1996.401
• ²⁷
  Daniels SR, Pratt CA, Hayman LL. Reduction of risk for cardiovascular disease in children and adolescents. Circulation. 2011;124(15):1673-86, https://doi.org/10.1161/CIRCULATIONAHA.110.016170
  » https://doi.org/10.1161/CIRCULATIONAHA.110.016170
• ²⁸
  Chubb H, Simpson JM. The use of Z-scores in paediatric cardiology. Ann Pediatr Cardiol. 2012;5(2):179-84, https://doi.org/10.4103/0974-2069.99622
  » https://doi.org/10.4103/0974-2069.99622
• ²⁹
  Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol. 2000;14(10-11):898-902, https://doi.org/10.1007/s004670000303
  » https://doi.org/10.1007/s004670000303
• ³⁰
  Canpolat N, Caliskan S, Sever L, Guzeltas A, Kantarci F, Candan C, et al. Glucose intolerance: is it a risk factor for cardiovascular disease in children with chronic kidney disease? Pediatr Nephrol. 2012;27(4):627-35, https://doi.org/10.1007/s00467-011-2034-3
  » https://doi.org/10.1007/s00467-011-2034-3
• ³¹
  Balzano R, Lindblad YT, Vavilis G, Jogestrand T, Berg UB, Krmar RT. Use of annual ABPM, and repeated carotid scan and echocardiography to monitor cardiovascular health over nine yr in pediatric and young adult renal transplant recipients. Pediatr Transplant. 2011;15(6):635-41, https://doi.org/10.1111/j.1399-3046.2011.01547.x
  » https://doi.org/10.1111/j.1399-3046.2011.01547.x
• ³²
  Kupferman JC, Aronson Friedman L, Cox C, Flynn J, Furth S, Warady B, et al. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol. 2014;25(1):167-74, https://doi.org/10.1681/ASN.2012121197
  » https://doi.org/10.1681/ASN.2012121197
• ³³
  Scavarda VT, Pinheiro AC, Costa SD, de Andrade ZM, Carvalhaes JT, Campos O, et al. Children with chronic renal disease undergoing dialysis or conservative treatment--differences in structural and functional echocardiographic parameters. Echocardiography. 2014;31(9):1131-7, https://doi.org/10.1111/echo.12525
  » https://doi.org/10.1111/echo.12525
• ³⁴
  Nagasako SS, Koch Nogueira PC, Machado PG, Medina Pestana JO. Arterial hypertension following renal transplantation in children-a short-term study. Pediatr Nephrol. 2003;18(12):1270-4, https://doi.org/10.1007/s00467-003-1297-8
  » https://doi.org/10.1007/s00467-003-1297-8
• ³⁵
  Nagasako SS, Nogueira PC, Machado PG, Pestana JO. Risk factors for hypertension 3 years after renal transplantation in children. Pediatr Nephrol. 2007;22(9):1363-8, https://doi.org/10.1007/s00467-007-0514-2
  » https://doi.org/10.1007/s00467-007-0514-2
• ³⁶
  Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356(9224):147-52, https://doi.org/10.1016/S0140-6736(00)02456-9
  » https://doi.org/10.1016/S0140-6736(00)02456-9
• ³⁷
  Doyon A, Fischer DC, Bayazit AK, Canpolat N, Duzova A, Sözeri B, et al. Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease. PLoS One. 2015;10(2):e0113482, https://doi.org/10.1371/journal.pone.0113482
  » https://doi.org/10.1371/journal.pone.0113482
• ³⁸
  Baroncini LA, Sylvestre Lde C, Pecoits Filho R. Assessment of Intima-Media Thickness in Healthy Children Aged 1 to 15 Years. Arq Bras Cardiol. 2016;106(4):327-32, https://doi.org/10.5935/abc.20160030
  » https://doi.org/10.5935/abc.20160030
• ³⁹
  Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol. 2012;7(12):1930-7, https://doi.org/10.2215/CJN.03130312
  » https://doi.org/10.2215/CJN.03130312

Publication Dates

• Publication in this collection
  19 June 2019
• Date of issue
  2019

History

• Received
  4 Sept 2018
• Accepted
  27 Feb 2019